Generate Biomedicines, Inc.

Healthcare · Biotechnology

17.10$ +9.2% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

Generate Biomedicines, Inc. (GENB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 32 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement GENB
Line item	2024	2025
Revenue	20	32
Gross Profit	20	32
Research & Development	175	225
Selling, General & Administrative	42	42
Total Operating Expenses	217	267
Operating Income	-197	-235
Interest Expense	2.1	1.1
Pre-Tax Income	-181	-223
Income Tax Expense	0.2	0.2
Net Income	-174	-203
EBITDA	-164	-208

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings